## FORM 4

obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Occident 10.1 onn 4 of 1 onn 5	

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Belldegrun Arie</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol Allogene Therapeutics, Inc. [ ALLO ]										ationship of Reportii k all applicable) Director Officer (give title below)		ing Person(s) to Issu 10% Own e Other (sp. below)			
(Last) (First) (Middle) 210 EAST GRAND AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 10/15/2018															
(Street) SOUTH SAN FRANCISCO CA 94080  (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year) 10/17/2018									. Indivine)	Form Form	lual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tabl	e I - No	n-Deriv	ative	Se	curitie	s Ac	quired,	Dis	posed o	f, or	Ben	eficia	ally	Owne	ed				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da				Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				and Sed Bed Ow		ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership						
								Code	v	Amount	Amount (A) or (D)		Price	- 1	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 10/15				10/15/	2018			<b>P</b> <sup>(1)</sup>		194,445		A	\$1	8	1,691,781			T I	See footnote <sup>(2)</sup>		
		Та									osed of, onvertib				y Ov	wned		,			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rcise (Month/Day/Year of tive	Transaction 3A. Deeme Execution			Transaction Code (Instr. I)		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Dat (Month/Day/Ye		or Nur of		str. 3  ount  mber	Deri Secu	Price of Privative Scurity Str. 5)	9. Number derivative Securities Beneficially General Following Reported Transaction (Instr. 4)	Owner Form Direct or Ind (I) (In	O. Ownership Form: Oirect (D) Oirect (D) Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

- $1.\ This\ transaction\ was\ inadvertently\ omitted\ from\ the\ reporting\ person's\ Form\ 4\ filed\ October\ 17,\ 2018.$
- 2. The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

## Remarks:

/s/ Veer Bhavnagri, Attorney-02/13/2019 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.